
The grant, which provides approximately $200,000 in research and development funds for a Phase I study, will allow the company to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy.
Characterization of nanoparticles and biologics is a critical step in the development of important new pharmaceutical therapeutics.
The company is backed by Merck Capital Ventures, LLC.
FinSMEs
19/04/2010